Otros idiomas Aileron Therapeutics, Inc.

Acciones

ALRN

US00887A2042

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 06/05/2024			Varia. Cinco días.	Varia. 1 de enero.
3,95 ^USD	+5,05 %		-19,72 %	+29,57 %

03/05	Aileron Therapeutics cierra una oferta directa de acciones y warrants	MT
01/05	Transcript : Aileron Therapeutics, Inc. - Special Call

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Aileron Therapeutics to Present at Two Upcoming Investor Conferences	06/05
Aileron Therapeutics Closes Direct Offering of Shares, Warrants	03/05
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million	03/05
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million	01/05
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)	01/05
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	01/05
Aileron Therapeutics : Corporate Presentation April 2024	15/04
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	15/04
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/04
Aileron Therapeutics : Management Change/Compensation - Form 8-K	29/03
Aileron Therapeutics, Inc. Announces CFO Changes	29/03
Aileron Therapeutics, Inc. Announces Board Changes	29/03
Aileron Therapeutics Names Brian Windsor as CEO	12/03
Aileron Therapeutics Announces CEO Transition	12/03
Aileron Therapeutics, Inc. Announces Appointment of Brian Windsor as President and to the Board of Directors	12/03
Aileron Therapeutics, Inc. Announces CEO Changes	12/03
Aileron Therapeutics, Inc. Announces Resignation of Nolan Sigal, M.D., Ph.D. from Board of Directors, Member of Nominating and Corporate Governance Committee	01/03
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event	15/02
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024	01/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Aileron Therapeutics, Inc.

Acciones

ALRN

US00887A2042

Otros idiomas

Filtros